Search - tctmd.com

Displaying 181 - 200 of 333

Sort: Relevancy | Date

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

Shelley Wood

January 31, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Todd Neale

January 26, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

Women Less Likely Than Men to Experience SCD During Sports

Michael O'Riordan

December 21, 2021

News Features

World-wise: As In-Person Meetings Resume, Global Voices Hope to Be Heard

Shelley Wood

December 13, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Conference News PCR London Valves 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Michael O'Riordan

November 26, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Todd Neale

November 17, 2021

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

Todd Neale

November 16, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Conference News EACTS 2021

TAVI Registries Offer Outcome Clues as Low-Risk Numbers Climb

Shelley Wood

October 20, 2021

News Opinion CV Team Dispatch

October 2021 News Roundup

L.A. McKeown

October 01, 2021

Advertisement

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

TCTMD’s Top 10 Most Popular Stories for January 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Women Less Likely Than Men to Experience SCD During Sports

World-wise: As In-Person Meetings Resume, Global Voices Hope to Be Heard

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 2021 News Roundup

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

Canagliflozin Improves Quality of Life in HF Patients

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 2021 News Roundup

TAVI Registries Offer Outcome Clues as Low-Risk Numbers Climb

October 2021 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content